Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Moderna to $225 from $185 and keeps a Buy rating on the shares. The analyst trimmed fiscal 2024 revenue estimates and thinks Moderna will now lose money this year given the "planned R&D burn." On the plus side, updates this week were incrementally positive, says the analyst, who lifed the price target to both reflect the positive recent news flow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Senator Sanders says Moderna COVID vaccine pricing shows ‘unacceptable’ greed
- Moderna (NASDAQ:MRNA) Set to Match Pfizer’s Price for COVID Vaccine
- Moderna considering $110-$130 for COVID shot, similar to Pfizer’s, WSJ says
- Moderna expects minimum Covid-19 vaccine sales of $5B in 2023
- Moderna announces updates on mRNA pipeline
